LONDON, UK — Achieving LDL-cholesterol levels less than 50 mg/dL with drug therapy, compared with baseline levels, is associated with lowered rates of major adverse cardiovascular events (MACE), but ...

High levels of low-density lipoprotein cholesterol (LDL-C) are a key risk factor for cardiovascular disease, which continues to be one of the leading causes of illness and death globally. LDL-C can ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

A high global mortality rate is associated with cardiovascular disease (CVD), particularly atherothrombotic ischaemic stroke and coronary heart disease. Therefore, it is necessary to reduce ...

Results from the PURSUIT Phase IIb trial for AstraZeneca’s (AZN) AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

Please provide your email address to receive an email when new articles are posted on . Lerodalcibep further reduced LDL vs. placebo in well-treated patients with HeFH. More than 85% of the ...

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with FDA approval for subcutaneous use. The LIBerate Program showed sustained ...

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...

A new lipid-lowering agent in a class that had been written off by many is being developed by a group of academic experts, with new data showing large LDL reductions on top of high-intensity statins.

A new oral PCSK9 inhibitor, enlicitide, offers a daily pill option for lowering LDL-C, a key cardiovascular disease risk factor. A clinical trial showed a significant 58.2% LDL-C reduction in patients ...